A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 05 Mar 2024 Status changed from recruiting to discontinued.
- 07 Jun 2022 Results (At the cut-off data of October 31 2021, n=39 )presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 25 Jan 2021 New trial record